MB BCh, PhD, FRCP
Professor of Metabolic Endocrinology
My work tries to better understand and treat metabolic diseases, in particular, non-alcholic fatty liver disease (NAFLD). Our work has focused on the role of steroid hormones and their metabolism in the development, assessment and treatment of metabolic diseases including NAFLD, obesity and type 2 diabetes. Our previous work has shown that altering steroid hormone metabolism can have a potent impact on the function of both liver and adipose tissue to store fat. Our future work will use steroid biomarkers not only to stage disease severity, but to predict progression. In addition, by altering tissue specific-metabolism, we hope to limit the side effects of prescribed steroids.
Long-Term Cardiometabolic Morbidity in Young Adults with Classic 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia
Righi B. et al, (2021), HORMONE RESEARCH IN PAEDIATRICS, 94, 69 - 70
Extensive weight loss reduces glycan age by altering IgG N-glycosylation.
Greto VL. et al, (2021), Int J Obes (Lond)
Systemic and adipocyte transcriptional and metabolic dysregulation in Idiopathic Intracranial Hypertension.
Westgate CS. et al, (2021), JCI Insight
Association of weight changes with changes in histological features and blood markers in non-alcoholic steatohepatitis
KOUTOUKIDIS D. et al, (2021), Clinical Gastroenterology and Hepatology
International practice of corticosteroid replacement therapy in congenital adrenal hyperplasia: data from the I-CAH registry.
Bacila I. et al, (2021), Eur J Endocrinol, 184, 553 - 563